MetaCap

AgomAb Therapeutics NV (AGMB) vs Lexeo Therapeutics (LXEO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $245.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%LXEO-58.66%
+26%-21%-68%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%LXEO-58.66%
+13%-27%-67%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus LXEO key metrics
MetricAGMBLXEO
Share price$5.45$2.96
Market cap$268.40M$245.05M
1-day change-3.02%+0.34%
YTD return—-70.19%
1-year return—-67.33%
EPS (TTM)$-2.08$-1.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-100.00M
52-week high$17.82$10.99
52-week low$5.39$2.55
Distance from 52-week high-69.42%-73.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+748.31%
Average volume208.99K1.98M
Shares outstanding49.25M82.79M
Employees6268
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Lexeo Therapeutics

LXEO stock →

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees

AGMB vs LXEO FAQ

Which is bigger, AgomAb Therapeutics NV or Lexeo Therapeutics?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $245.05M for Lexeo Therapeutics (LXEO).

Are AgomAb Therapeutics NV and Lexeo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons